It has been shown that arsenic trioxide directly binds to cysteine residues in the zinc fingers located in the RBCC domain of PML, triggering the SUMOylation and degradation of the fusion protein PML‐RARα.[8] Therefore, looking for novel inorganics that effectively treat hematological tumors via targeted degradation of oncoproteins (e.g., AML1‐ETO) may be a promising strategy to defeat leukemia. Here, RARA is linked to leukemia.